se ha leído el artículo
array:19 [ "pii" => "X0211699504029778" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:11-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2581 "formatos" => array:3 [ "EPUB" => 227 "HTML" => 1872 "PDF" => 482 ] ] "itemSiguiente" => array:15 [ "pii" => "X021169950402976X" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:13" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7855 "formatos" => array:3 [ "EPUB" => 253 "HTML" => 6933 "PDF" => 669 ] ] "es" => array:8 [ "idiomaDefecto" => true "titulo" => "Hipertensión esencial, sensibilidad a la sal y riesgo cardiovascular" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "13" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. COCA" "autores" => array:1 [ 0 => array:1 [ "nombre" => "A. COCA" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169950402976X?idApp=UINPBA000064" "url" => "/02116995/00000024000000S1/v0_201502091335/X021169950402976X/v0_201502091335/es/main.assets" ] "itemAnterior" => array:15 [ "pii" => "X0211699504029786" "issn" => "02116995" "estado" => "S300" "fechaPublicacion" => "2004-02-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2004;24 Supl 1:10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2050 "formatos" => array:3 [ "EPUB" => 221 "HTML" => 1380 "PDF" => 449 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "10" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. DE ZEEUW" "autores" => array:1 [ 0 => array:1 [ "nombre" => "D. DE ZEEUW" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029786?idApp=UINPBA000064" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Efecto del losartan sobre la muerte cardíaca súbita en personas con diabetes: estudio LIFE" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "11" "paginaFinal" => "12" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. LINDHOLM" "autores" => array:1 [ 0 => array:1 [ "nombre" => "L. LINDHOLM" ] ] ] ] "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Efecto del losartán sobre la muerte cardíaca súbita en personas con diabetes: estudio LIFE L. Lindholm Umea University Hospital. Sweden. Sudden cardiac death prevention in coronary heart disease is an important goal for treatment. In placebo controlled long-term studies, several beta-blockers including atenolol have shown consistent reductions in post-infarction mortality by up to 50% reduction in the risk of sudden cardiac death 1. It has been suggested that in patients with diabetes mellitus, particularly if associated with autonomic neuropathy, increase in heart rate and decrease in heart rate variability may be critical risk factors for sudden cardiac death and increased all-cause mortality. In a pre-specified subgroup of diabetics (n = 1,195) with left ventricular hypertrophy, the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported a major reduction of all-cause mortality and especially cardiovascular mortality with a losartan-based vs an atenolol-based antihypertensive therapy 1. Against this background, we hypothesised post-hoc that the losartan-based therapy may have affected sudden cardiac death better than atenolol-based therapy. As part of the main LIFE study, and in a doublemasked, randomised, parallel-group design, 1,195 men and women (53% women) with diabetes, hypertension (mean age 67 years, average pressure 177/96 mmHg after placebo run-in) and ECG-documented left ventricular hypertrophy, were assigned once-daily losartan- or atenolol-based antihypertensive therapy and followed for at least 4 years (mean 4.7 years) 1. Baseline data as well as treatment profile are given in 1. In both groups, around 85% received a diuretic as supplementary treatment. Cox regression analysis with baseline Framingham risk score and ECG-LVH as covariates was used to compare effects of the two regimens on cardiovascular morbidity and mortality (defined as cardiovascular death, stroke, or myocardial infarction). An independent end-point committee, masked to the type of treatment the patients had received, classified all endpoints including sudden cardiac death. As previously reported 1, there were fewer (p = 0.028) cardiovascular deaths in the losartan group than in the atenolol group and there was a similar tendency (p = 0.052) for coronary deaths. When analysed separately, there was significantly less (p = 0.027) sudden cardiac deaths in the losartan-based group (14 patients) than in the atenolol-based group (30 patients), as shown in table I and figure 1. This tended to be so, regardless of whether deaths occurred within one hour or within 24 hours of symptom onset (table I). Our finding that the risk was lower in the losartan-treated diabetics than in those who received atenolol was independent of other risk factors for sudden cardiac death. A difference in regression of LVH between the two treatment groups of diabetics did not explain the difference in sudden cardiac death. The last serum potassium value before sudden death (mean and standard deviation) was similar, 4.26 (0.42) mmol/L in the losartan-based group and 4.23 (0.40) mmol/L in the atenolol-based group (NS); the change from baseline was 0.01 mmol/L in both groups. In the non-diabetics of the LIFE trial, there were equal numbers of sudden cardiac deaths (67 patients) in the two treatment groups. The results from the diabetic subgroup in the LIFEstudy, showing a much lower rate of cardiovascular death and total death in losartan-treated patients than in atenolol-treated patients 5, prompted us to carry out a post-hoc analysis of sudden cardiac death. To our surprise, the analysis showed a close to 50% risk reduction in sudden death in losartan treated diabetic patients as compared to atenolol-treated patients, whereas this was not so in the non-diabetics. The results should be viewed against the background that beta-blockers are known to offer protection against cardiovascular death and sudden cardiovascular death, particularly in patients with active coronary heart disease. A possible explanation for the better outcome in the losartan group is a better anti-arrhythmic property of losartan as compared to atenolol. Our data showed that among patients with diabetes, 19 (9.9%) of those with atrial fibrillation (n = 191) at baseline or during the trial, died of sudden cardiac death. In the diabetics without atrial fibrillation (n = 1,004), 25 (2.5%) died of sudden cardiac death. The corresponding figures for the losartan 11 L. LINDHOLM group were 5 of 86 (6%) vs 9 of 500 (2%) and in the atenolol group 14 of 105 (13%) vs 16 of 504 (3%). Study drug discontinuation, particularly discontinuation of atenolol, did not explain these differences. It should be underlined that the number of sudden cardiac deaths (n = 44) in the present analyses comprised 44% of all cardiovascular deaths and 26% of all deaths in the LIFE diabetics during follow-up. It is known from experimental studies, as well as analyses of the LIFE study, that losartan as compared to atenolol reduced the risk of episodes of atrial fibrillation. It is likely that losartan, by leading to regression of left ventricular hypertrophy and possibly less atrial fibrosis, would favor an anti-arrhythmic effect. It is also known from the LIFE study that abnormalities in QT-dispersion and heart rate variability are related to left ventricular hypertrophy, possibly by left ventricular hypertrophy-induced repolarization abnormalities. A modulation of sympathetic nerve activity might be involved as well. It is known from clinical and experimental work that ACE-inhibition, and also angiotensin-II antagonism, might inhibit sympathetic nervous system by a blunting of the facilitating effect of angiotensin-II on sympathetic tone. Finally, and importantly, our analyses were exploratory and require confirmation. REFERENCES 1. Yusuf S, Wittes J, Friedman L: Overview of results of randomised clinical trials in heart disease. I. Treatment following myocardial infarction. JAMA 260: 2088-93, 1988. 2. Singh N: Diabetes, heart rate and mortality. J Cardiovasc Pharmacol Ther 7: 117-29, 2002. 3. Dellsperger KC, Martins JB, Clothier JL, Marcus ML: Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta-adrenergic blockade. Circulation 82: 941-50, 1990. 4. Reiter MJ: Beta-adrenergic blocking drugs as antifibrillatory agents. Curr Cardiol Rep 4: 426-33, 2002. 5. Lindholm LH, Ibsen H, Dahlöf B y cols.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 100410, 2002. 12 " "pdfFichero" => "P7-E232-S132-A2968.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029778/v0_201502091335/en/main.assets" "Apartado" => array:4 [ "identificador" => "35393" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Artículos Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029778/v0_201502091335/en/P7-E232-S132-A2968.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029778?idApp=UINPBA000064" ]
Idioma original: Inglés
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 8 | 13 | 21 |
2024 Octubre | 47 | 35 | 82 |
2024 Septiembre | 53 | 23 | 76 |
2024 Agosto | 57 | 60 | 117 |
2024 Julio | 43 | 22 | 65 |
2024 Junio | 68 | 42 | 110 |
2024 Mayo | 60 | 28 | 88 |
2024 Abril | 41 | 36 | 77 |
2024 Marzo | 30 | 21 | 51 |
2024 Febrero | 28 | 34 | 62 |
2024 Enero | 37 | 24 | 61 |
2023 Diciembre | 26 | 22 | 48 |
2023 Noviembre | 33 | 25 | 58 |
2023 Octubre | 32 | 29 | 61 |
2023 Septiembre | 23 | 28 | 51 |
2023 Agosto | 33 | 31 | 64 |
2023 Julio | 35 | 23 | 58 |
2023 Junio | 36 | 30 | 66 |
2023 Mayo | 41 | 35 | 76 |
2023 Abril | 25 | 20 | 45 |
2023 Marzo | 24 | 26 | 50 |
2023 Febrero | 28 | 36 | 64 |
2023 Enero | 60 | 38 | 98 |
2022 Diciembre | 38 | 45 | 83 |
2022 Noviembre | 43 | 32 | 75 |
2022 Octubre | 31 | 42 | 73 |
2022 Septiembre | 28 | 40 | 68 |
2022 Agosto | 36 | 41 | 77 |
2022 Julio | 32 | 65 | 97 |
2022 Junio | 21 | 38 | 59 |
2022 Mayo | 32 | 41 | 73 |
2022 Abril | 30 | 51 | 81 |
2022 Marzo | 30 | 54 | 84 |
2022 Febrero | 27 | 28 | 55 |
2022 Enero | 29 | 47 | 76 |
2021 Diciembre | 32 | 41 | 73 |
2021 Noviembre | 27 | 34 | 61 |
2021 Octubre | 28 | 45 | 73 |
2021 Septiembre | 32 | 37 | 69 |
2021 Agosto | 26 | 44 | 70 |
2021 Julio | 39 | 31 | 70 |
2021 Junio | 21 | 27 | 48 |
2021 Mayo | 28 | 37 | 65 |
2021 Abril | 40 | 39 | 79 |
2021 Marzo | 36 | 26 | 62 |
2021 Febrero | 27 | 17 | 44 |
2021 Enero | 24 | 20 | 44 |
2020 Diciembre | 31 | 11 | 42 |
2020 Noviembre | 18 | 17 | 35 |
2020 Octubre | 14 | 14 | 28 |
2020 Septiembre | 23 | 11 | 34 |
2020 Agosto | 39 | 10 | 49 |
2020 Julio | 31 | 10 | 41 |
2020 Junio | 26 | 12 | 38 |
2020 Mayo | 30 | 18 | 48 |
2020 Abril | 37 | 16 | 53 |
2020 Marzo | 37 | 14 | 51 |
2020 Febrero | 48 | 17 | 65 |
2020 Enero | 61 | 23 | 84 |
2019 Diciembre | 48 | 27 | 75 |
2019 Noviembre | 64 | 18 | 82 |
2019 Octubre | 28 | 9 | 37 |
2019 Septiembre | 43 | 17 | 60 |
2019 Agosto | 27 | 14 | 41 |
2019 Julio | 29 | 25 | 54 |
2019 Junio | 23 | 14 | 37 |
2019 Mayo | 25 | 35 | 60 |
2019 Abril | 57 | 39 | 96 |
2019 Marzo | 15 | 15 | 30 |
2019 Febrero | 10 | 30 | 40 |
2019 Enero | 17 | 16 | 33 |
2018 Diciembre | 34 | 26 | 60 |
2018 Noviembre | 43 | 14 | 57 |
2018 Octubre | 36 | 9 | 45 |
2018 Septiembre | 28 | 10 | 38 |
2018 Agosto | 18 | 10 | 28 |
2018 Julio | 22 | 15 | 37 |
2018 Junio | 17 | 7 | 24 |
2018 Mayo | 17 | 11 | 28 |
2018 Abril | 28 | 5 | 33 |
2018 Marzo | 17 | 7 | 24 |
2018 Febrero | 19 | 3 | 22 |
2018 Enero | 20 | 5 | 25 |
2017 Diciembre | 27 | 3 | 30 |
2017 Noviembre | 14 | 3 | 17 |
2017 Octubre | 22 | 5 | 27 |
2017 Septiembre | 11 | 4 | 15 |
2017 Agosto | 13 | 6 | 19 |
2017 Julio | 14 | 5 | 19 |
2017 Junio | 8 | 5 | 13 |
2017 Mayo | 16 | 5 | 21 |
2017 Abril | 14 | 3 | 17 |
2017 Marzo | 15 | 2 | 17 |
2017 Febrero | 6 | 0 | 6 |
2017 Enero | 9 | 2 | 11 |
2016 Diciembre | 12 | 10 | 22 |
2016 Noviembre | 26 | 7 | 33 |
2016 Octubre | 29 | 4 | 33 |
2016 Septiembre | 56 | 2 | 58 |
2016 Agosto | 71 | 1 | 72 |
2016 Julio | 89 | 2 | 91 |
2016 Junio | 69 | 0 | 69 |
2016 Mayo | 69 | 0 | 69 |
2016 Abril | 43 | 0 | 43 |
2016 Marzo | 27 | 0 | 27 |
2016 Febrero | 57 | 0 | 57 |
2016 Enero | 47 | 0 | 47 |
2015 Diciembre | 65 | 0 | 65 |
2015 Noviembre | 64 | 0 | 64 |
2015 Octubre | 43 | 0 | 43 |
2015 Septiembre | 40 | 0 | 40 |
2015 Agosto | 42 | 0 | 42 |
2015 Julio | 33 | 0 | 33 |
2015 Junio | 23 | 0 | 23 |
2015 Mayo | 23 | 0 | 23 |
2015 Abril | 7 | 0 | 7 |